Clinical trials: Major Depressive Disorder, completed
Major Depression
RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD
To compare the clinical efficacy of XingpiJieyu formula or its placebo combined with Escitalopram (ESC) in the treatment of moderate and severe MDD, and to explore a new method of integrated traditional Chinese and western…
- Trial name
- NCT06758167
- Testing
- XingpiJieyu formula, Escitalopram
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Peking University Sixth Hospital
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control.
- Trial name
- NCT00385307
- Testing
- amibegron (SR58611A)
- Where
- United States
- Volunteers
- 680 people
- Sponsor
- Sanofi
Major Depressive Disorder
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults.
- Trial name
- NCT00109044
- Testing
- Escitalopram
- Where
- 18 sites in United States
- Volunteers
- 540 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression
The long-term goal of this line of research is to determine if decreased vascular reactivity and frontal hypoperfusion is associated with poor response antidepressants.
- Trial name
- NCT01896934
- Testing
- Sertraline
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University
Condition: Major Depressive Disorder (MDD)
The Modulatory Role of Communicated Treatment Rationale on Treatment Expectation Effects in Depression.
Placebo groups in clinical trials on depression show impressive improvements. Yet, there is little research on the mechanism underlying this effect.
- Trial name
- NCT04719663
- Testing
- Biological illness and treatment rationale, Psychological illness and treatment rationale
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Philipps University Marburg
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Major Depressive Disorder
Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
The purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.
- Trial name
- NCT00135421
- Testing
- Pexacerfont, Escitalopram
- Where
- 45 sites in United States
- Volunteers
- 271 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.
- Trial name
- NCT00694304
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 535 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04533529
- Testing
- Seltorexant
- Where
- 122 sites in United States, Brazil and 9 more
- Volunteers
- 588 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Major Depressive Disorder
Diet and Depression
This study is a pilot open label crossover trial to assess the feasibility and acceptability of reducing ultra- processed foods (UPF) in a personalized manner from the diets of patients with major depressive disorder who eat a…
- Conditions
- Depression, Major Depressive Disorder, Weight Gain, Obesity
- Trial name
- NCT06252701
- Testing
- Reduction of Ultra-processed foods
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder
A Study of Xiongdan Wan Treating Depression
This is a prospective, single-arm, open-label study to evaluate the safety and efficacy of Xiongdan Wan monotherapy in patients with Major Depressive Disorder(MDD), conducted in Shang Hai Mental Health Center.
- Trial name
- NCT05136365
- Testing
- Xiongdan Wan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
We propose to determine if augmentation of electroconvulsive therapy (ECT) utilized for the treatment of major depressive disorder (MDD) with daily oral creatine will lead to an accelerated response to treatment, an overall…
- Trial name
- NCT04504253
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Utah
Major Depressive Disorder
Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer
The purpose of this study is to determine if monoamine oxidase B (MAO-B) total distribution volume (VT), after phenelzine treatment and if so to what extent.
- Trial name
- DETB (NCT02153281)
- Testing
- phenelzine treatment
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depression (in Remission)
Investigating the Mechanisms of Mindfulness-based Cognitive Therapy (MBCT)
This research will investigate the neuropsychological mechanisms underlying the eight-week Mindfulness-based Cognitive Therapy (MBCT) programme.
- Trial name
- NCT02226042
- Testing
- Mindfulness-based Cognitive Therapy
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Major Depressive Disorder
Long-term Study With Trazodone Once-a-Day
The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute…
- Trial name
- NCT04295941
- Testing
- TraZODone Hydrochloride 300 MG
- Where
- Bulgaria
- Volunteers
- 200 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Major Depressive Disorder, Recurrent
The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse
This research proposal is intended to elucidate the efficacy and mechanisms underlying Mindfulness Based Cognitive Therapy (MBCT) in a population in remission from recurrent Major Depressive Disorder (MDD).
- Trial name
- MBCT (NCT01145872)
- Testing
- Mindfulness Based Cognitive Therapy, Health Enhancement Program
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of Denver
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Assessment of Cognitive Functioning Before and After Treatment With Duloxetine
The purpose of this study is to study the effect of duloxetine treatment on (1) cognitive functions, the brain mechanisms involved with thinking, reasoning, learning, and remembering; (2) psychosocial functions, how someone…
- Trial name
- DULOX (NCT00933439)
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Cognitive Dysfunction, Burns
PRIME: Cognitive Outcome Following Major Burns
PRIME aims to demonstrate through neurocognitive assessment that BICU patients will have a degree of neurocognitive dysfunction following a major burn, that this neurocognitive dysfunction is due to an underlying…
- Conditions
- Cognitive Dysfunction, Burns, Inflammation, Brain, Quality of Life
- Trial name
- PRIME (NCT03242395)
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.